Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease

This study has been terminated.
(Study was terminated early by the Sponsor due to unblinding between study drug and placebo groups at the subject, site and Sponsor levels.)
Sponsor:
Information provided by (Responsible Party):
Baxalta US Inc.
ClinicalTrials.gov Identifier:
NCT01987908
First received: October 29, 2013
Last updated: February 3, 2017
Last verified: November 2016
  Purpose

Sickle cell disease (SCD) is a genetic blood disorder characterized by the presence of sickle-shaped red blood cells. In the U.S. and the U.K. this occurs primarily in persons of African origin. There is only one drug (hydroxyurea) approved to manage SCD, but it is not fully efficacious and can produce medically significant side effects. Aes-103 is being evaluated as a novel agent for the long term management of SCD. By directly reducing the sickling process, Aes-103 has a different mechanism of action than hydoxyurea. The active ingredient in Aes-103 is 5-hydroxymethyl furfural, a naturally occurring small molecule that is chemically related to glucose.

This study will evaluate the safety and pharmacokinetic profile of two dosing regimens of Aes-103 for up to 28 days in up to 50 adult subjects with stable SCD compared with subjects receiving placebo.


Condition Intervention Phase
Sickle Cell Disease
Drug: Aes-103
Other: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator
Primary Purpose: Treatment
Official Title: A Phase 2, Exploratory, Placebo-Controlled, Multicenter, Double-Blind Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Two Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease

Resource links provided by NLM:


Further study details as provided by Baxalta US Inc.:

Primary Outcome Measures:
  • Number of Participants With Adverse Events, Including Sickle Cell-specific Symptoms, During the Double-blind Treatment Period [ Time Frame: Double-blind treatment period of 28 days (Day 1 to Day 28) ]
    Number of participants with adverse events (AEs) reported during the double-blind treatment period. AEs included clinically-significant changes in vital signs, ECG, clinical laboratory assessments, physical and neurological examinations. Sickle cell-specific symptoms included the development of new skin ulcers, hospitalization or ambulatory acute care, intravenous analgesics visit for pain episodes (i.e., sickle-cell disease related pain), acute chest syndrome, priapism, and stroke.

  • Number of Participants With Adverse Events, Including Sickle-cell Specific Symptoms, During the Placebo lead-in Period [ Time Frame: Placebo lead-in period of 14 days (Day -14 to Day -1) ]
    Number of participants with adverse events (AEs) reported during the placebo lead-in period. AEs included clinically-significant changes in vital signs, ECG, clinical laboratory assessments, physical and neurological examinations. Sickle cell-specific symptoms included the development of new skin ulcers, hospitalization or ambulatory acute care, intravenous analgesics visit for pain episodes (i.e., sickle-cell disease related pain), acute chest syndrome, priapism, and stroke.

  • Number of Participants With Adverse Events, Including Sickle-cell Specific Symptoms, During the Post-treatment Observation Period [ Time Frame: Post-treatment observation period of 21 days (Day 29 to Day 49) ]
    Number of participants with adverse events (AEs) reported during the post-treatment observation period. AEs included clinically-significant changes in vital signs, ECG, clinical laboratory assessments, physical and neurological examinations. Sickle cell-specific symptoms included the development of new skin ulcers, hospitalization or ambulatory acute care, intravenous analgesics visit for pain episodes (i.e., sickle-cell disease related pain), acute chest syndrome, priapism, and stroke.

  • Number of Participants With Sickle-Cell Disease-related Symptoms [ Time Frame: Placebo lead-in period of 14 days (Day -14 to Day -1), double-blind treatment period of 28 days (Day 1 to Day 28) and post-treatment observation period of 21 days (Day 29 to Day 49) ]
  • Number of Clinically Significant Observations of Vital Signs, 12-lead ECGs, Clinical Laboratory Assessments, and Physical and Neurological Examinations [ Time Frame: Throughout the study period (approximately 9 weeks) ]
    Vital signs, 12-lead ECGs, clinical laboratory assessments, and physical and neurological examinations that were deemed clinically significant by the investigator in agreement with the sponsor study director.

  • PK: - Plasma AUC, Cmax, Tmax, and T1/2 of Aes-103 and Its Metabolite, HMFA - RBC Hemolysate AUC (0-8h), Cmax, Tmax, and T1/2 of Aes-103 - Percentage of Hemoglobin Bound to Aes-103 [ Time Frame: PK blood samples were to be taken within 10 minutes before dosing and 0.5, 1, 2, 4, and 6 hours after the first dose of study product on Days 1 and 7 and at the same time points on Day 28 (or early termination) ]

    Pharmacokinetic endpoints in the study protocol were as follows:-

    • Plasma Area under curve (AUC), Maximum plasma concentration (Cmax), time at which Cmax observed (Tmax), and terminal half-life (T1/2) of Aes-103 and its metabolite, 5-hydroxymethyl-2-furoic acid (HMFA)
    • red blood cell (RBC) hemolysate Area under curve between 0 and 8 hours (AUC [0-8h]), Cmax, Tmax, and T1/2 of Aes-103
    • Percentage of hemoglobin bound to Aes-103


Secondary Outcome Measures:
  • Resting Oxygen Saturation as Measured by Oximetry (SpO2) - Change From Baseline [ Time Frame: Prior to, during and after the end of dosing in the double-blind treatment period, i.e., at baseline, Day 4, Day 7, Day 14 and Day 28 ]

    A measure of the amount of oxygen in the blood. Oxygen saturation was determined by pulse oximetry. A pulse oximeter was placed over a nail polish-free finger nail to determine peripheral oxygen saturation (SpO2).

    Baseline was defined as the most recent value obtained prior to the start of dosing on Day 1 of the double-blind treatment period. A mean change from baseline >0 indicates an increase in oxygen saturation, a mean change <0 indicates a decrease in oxygen saturation.

    Category title includes number of participants with available data (n) for participants treated with study product, followed by participants treated with placebo.


  • Oxygen Binding p50/p20 Value - Change From Baseline [ Time Frame: During the double-blind treatment period at baseline, Day 1, Day 4 and Day 7 ]

    A measure of the ability of hemoglobin to bind oxygen. The p50 is the oxygen level at which 50% of the hemoglobin contains oxygen. The p20 is the oxygen level at which 20% of the hemoglobin contains oxygen. Baseline is defined as the most recent value obtained prior to start of dosing on Day 1 of the double-blind treatment period.

    Category title includes number of participants with available data (n) for participants treated with study product, followed by participants treated with placebo.


  • Plasma Erythropoietin (EPO) Levels - Change From Baseline [ Time Frame: At baseline and Day 28 during the double-blind treatment period ]

    Erythropoietin (EPO) is a hormone produced by the kidney that promotes the formation of red blood cells by the bone marrow. EPO can be detected and measured in the blood.

    Baseline defined as the most recent value obtained prior to the start of dosing on Day 1 of the double-blind treatment period.

    Category title includes number of participants with available data (n) for participants treated with study product, followed by participants treated with placebo.


  • Hematocrit Levels - Change From Baseline [ Time Frame: Prior to, during and after the end of dosing in the double-blind treatment period, i.e., at baseline, Day 1, Day 7, Day 14 and Day 28 ]

    Baseline defined as the most recent value obtained prior to the start of dosing on Day 1 of the double-blind treatment period.

    Category title includes number of participants with available data (n) for participants treated with study product, followed by participants treated with placebo.


  • Lactate Dehydrogenase (LDH) Levels - Change From Baseline [ Time Frame: Prior to, during and after the end of dosing in the double-blind treatment period, i.e., at baseline, Day 1, Day 7, Day 14 and Day 28 ]

    LDH levels were measured as a biomarker for intravascular hemolysis. The results are based on the LDH Total measurement. Baseline defined as the most recent value obtained prior to the start of dosing on Day 1 of the double-blind treatment period.

    Category title includes number of participants with available data (n) for participants treated with study product, followed by participants treated with placebo.


  • Hemoglobin Levels - Change From Baseline [ Time Frame: Prior to, during and after the end of dosing in the double-blind treatment period, i.e., at baseline, Day 1, Day 4, Day 7, Day 14, Day 21 and Day 28 ]

    A clinical laboratory endpoint that reflects the amount of red blood cells present in the blood. Baseline defined as the most recent value obtained prior to the start of dosing on Day 1 of the double-blind treatment period.

    Category title includes number of participants with available data (n) for participants treated with study product, followed by participants treated with placebo.


  • Reticulocyte Percent- Change From Baseline [ Time Frame: At baseline, Day 1 and Day 7 during the double-blind treatment period ]
    Category title includes number of participants with available data (n) for participants treated with study product.

  • Direct Bilirubin - Change From Baseline [ Time Frame: Prior to, during and after the end of dosing in the double-blind treatment period, i.e., at baseline, Day 1, Day 7, Day 14, Day 21 and Day 28 ]
    Category title includes number of participants with available data (n) for participants treated with study product, followed by participants treated with placebo.

  • LDH Isoform - Change From Baseline [ Time Frame: Prior to, during and after the end of dosing in the double-blind treatment period, i.e., at baseline, Day 1, Day 7, Day 14 and Day 28 ]
  • C Reactive Protein Levels - Change From Baseline [ Time Frame: At baseline, Day 1 and Day 7 during the double-blind treatment period ]
    Category title includes number of participants with available data (n) for participants treated with study product.

  • Serum Ferritin Levels - Change From Baseline [ Time Frame: At baseline, Day 1 and Day 7 during the double-blind treatment period ]
  • N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) Levels- Change From Baseline [ Time Frame: At baseline, Day 1, Day 7, Day 14 and Day 28 during the double-blind treatment period ]
    Category title includes number of participants with available data (n) for participants treated with study product.

  • Body Weight - Change From Baseline [ Time Frame: Prior to, during and after the end of dosing in the double-blind treatment period, i.e., at baseline, Day 1, Day 4, Day 7, Day 14, Day 21 and Day 28 ]

    A negative change in body weight denotes a weight decrease, a positive change in body weight denotes a weight increase.

    Category title includes number of participants with available data (n) for participants treated with study product, followed by participants treated with placebo.


  • Exercise Tolerance: 6-Minute Walk Distance During the Double-blind Treatment Period - Change From Baseline [ Time Frame: Prior to, during and after the end of dosing in the double-blind treatment period, i.e., at baseline, Day 4, Day 7, Day 14 and Day 28 ]

    Functional exercise capacity was evaluated by using the 6-minute walk test (6MWT) which measures the distance that a subject can quickly walk on a flat, hard surface in a period of 6 minutes. Guidelines developed by the American Thoracic Society were used for conducting the test and interpreting the results.

    Baseline defined as the most recent value obtained prior to the start of dosing on Day 1.

    Category title includes number of participants with available data (n) for participants treated with study product, followed by participants treated with placebo.


  • Exercise Tolerance: 6-Minute Walk Distance on Day 49 of the Post-treatment Observation Period - Change From Baseline [ Time Frame: Prior to dosing at baseline and on Day 49 of the post-treatment observation period ]

    Functional exercise capacity was evaluated by using the 6-minute walk test (6MWT) which measures the distance that a subject can quickly walk on a flat, hard surface in a period of 6 minutes. Guidelines developed by the American Thoracic Society were used for conducting the test and interpreting the results.

    Baseline defined as the most recent value obtained prior to the start of dosing on Day 1.


  • Exercise Tolerance: 6-Minute Walk Distance on Day 49 of the Post-treatment Observation Period - Change From Last Day of Double-blind Treatment Period (Day 28) [ Time Frame: On last day of double-blind treatment period (Day 28) and on Day 49 of the post-treatment observation period ]
    Functional exercise capacity was evaluated by using the 6-minute walk test (6MWT) which measures the distance that a subject can quickly walk on a flat, hard surface in a period of 6 minutes. Guidelines developed by the American Thoracic Society were used for conducting the test and interpreting the results.

  • Exercise Tolerance: Cardiopulmonary Exercise Test [CPET] [ Time Frame: On last day of double-blind treatment period (Day 28) ]
    CPET was optional, based on capacity of participant to complete the test.

  • Patients´ Global Impression of Change (PGIC) During the Double-blind Treatment Period - Change From Baseline [ Time Frame: At baseline and once weekly on Days 7, 14, 21, and 28 during the double-blind treatment period ]

    Participants assessed the change in activity limitations, symptoms, emotions, and overall quality of life by using the 1- to 7-point PGIC scale. The question and scale was as follows: Since beginning treatment at this clinic, how would you describe the change in your sickle cell condition? Please circle the number that matches your overall judgment. -3 - much worse -2 - moderately worse -1 - minimally worse 0 - no change +1 - minimally improved +2 - moderately improved +3 - much improved.

    Baseline defined as the most recent value obtained prior to the start of dosing on Day 1 of the double-blind treatment period. No values available for placebo group for Day 28.

    Category title includes number of participants with available data (n) for participants treated with study product, followed by participants treated with placebo.


  • Patients´ Global Impression of Change (PGIC) During the Post-treatment Observation Period - Change From Baseline [ Time Frame: At baseline and once weekly on Days 35, 42, and 49 during the post-treatment observation period ]

    Participants assessed the change in activity limitations, symptoms, emotions, and overall quality of life by using the 1- to 7-point PGIC scale. The question and scale was as follows: Since beginning treatment at this clinic, how would you describe the change in your sickle cell condition? Please circle the number that matches your overall judgment. -3 - much worse -2 - moderately worse -1 - minimally worse 0 - no change +1 - minimally improved +2 - moderately improved +3 - much improved.

    Baseline defined as the most recent value obtained prior to the start of dosing on Day 1 of the double-blind treatment period.

    Category title includes number of participants with available data (n) for participants treated with study product, followed by participants treated with placebo.


  • Patients´ Global Impression of Change (PGIC) During the Post-treatment Observation Period - Change From Last Day of Double-blind Treatment Period [ Time Frame: At baseline and once weekly on Days 35, 42, and 49 during the post-treatment observation period ]

    Participants assessed the change in activity limitations, symptoms, emotions, and overall quality of life by using the 1- to 7-point PGIC scale. The question and scale was as follows: Since beginning treatment at this clinic, how would you describe the change in your sickle cell condition? Please circle the number that matches your overall judgment. -3 - much worse -2 - moderately worse -1 - minimally worse 0 - no change +1 - minimally improved +2 - moderately improved +3 - much improved.

    Baseline was defined as the most recent value obtained on the last day of the double-blind treatment period.

    Categories contain Category title includes number of participants with available data (n) for participants treated with study product, followed by participants treated with placebo.


  • Numerical Pain Rating Scale (NPRS): Worst Pain (Weekly Average) in the Double-blind Treatment Period - Change From Baseline [ Time Frame: Participants assessed and recorded their pain level daily. Weekly averages were calculated for the Day 7, Day 14, Day 21, and Day 28 assessments ]

    Participants assessed their pain levels by using the 0-10 Numeric Rating Scale: 0 = No pain 1-3 = Mild pain (nagging, annoying, interfering little with activities of daily living [ADLs]) 4-6 = Moderate pain (interferes significantly with ADLs) 7-10 = Severe pain (disabling; unable to perform ADLs A negative mean change denotes a pain decrease. A positive mean change denotes an increase in pain. Baseline was defined as the average of all measures taken from screening through the period prior to start of dosing on Day 1.

    Category title includes number of participants with available data (n) for participants treated with study product, followed by participants treated with placebo.


  • Numerical Pain Rating Scale (NPRS): Worst Pain (Weekly Average) in the Double-blind Treatment Period - AUC [ Time Frame: Participants assessed and recorded their pain level daily. Weekly averages were calculated for the Day 7, Day 14, Day 21, and Day 28 assessments ]
    Participants assessed their pain levels by using the 0-10 Numeric Rating Scale: 0 = No pain 1-3 = Mild pain (nagging, annoying, interfering little with activities of daily living [ADLs]) 4-6 = Moderate pain (interferes significantly with ADLs) 7-10 = Severe pain (disabling; unable to perform ADLs A negative mean change denotes a pain decrease. A positive mean change denotes an increase in pain. Baseline was defined as the average of all measures taken from screening through the period prior to start of dosing on Day 1. Area under the curve (AUC) was computed using change from baseline in weekly average values at Day 7, Day 14, Day 21. and Day 28.

  • Numerical Pain Rating Scale (NPRS): Worst Pain (Weekly Average) in the Post-treatment Observation Period - Change From Baseline [ Time Frame: Participants assessed and recorded their pain level daily. Weekly averages were calculated for the Day 35, Day 42 and Day 49 assessments ]

    Participants assessed their pain levels by using the 0-10 Numeric Rating Scale: 0 = No pain 1-3 = Mild pain (nagging, annoying, interfering little with activities of daily living [ADLs]) 4-6 = Moderate pain (interferes significantly with ADLs) 7-10 = Severe pain (disabling; unable to perform ADLs A negative mean change denotes a pain decrease. A positive mean change denotes an increase in pain. Baseline was defined as the average of all measures taken from screening through the period prior to start of dosing on Day 1.

    Category title includes number of participants with available data (n) for participants treated with study product, followed by participants treated with placebo.


  • Numerical Pain Rating Scale (NPRS): Worst Pain (Weekly Average) in the Post-treatment Observation Period - AUC [ Time Frame: Participants assessed and recorded their pain level daily. Weekly averages were calculated for the Day 35, Day 42 and Day 49 assessments ]
    Participants assessed their pain levels by using the 0-10 Numeric Rating Scale: 0 = No pain 1-3 = Mild pain (nagging, annoying, interfering little with activities of daily living [ADLs]) 4-6 = Moderate pain (interferes significantly with ADLs) 7-10 = Severe pain (disabling; unable to perform ADLs A negative mean change denotes a pain decrease. A positive mean change denotes an increase in pain. Baseline was defined as the average of all measures taken from screening through the period prior to start of dosing on Day 1. Area under the curve (AUC) was computed using change from baseline in weekly average values at Day 7, Day 14, Day 21, Day 28, Day 35, Day 42 and Day 49.

  • Numerical Pain Rating Scale (NPRS): Worst Pain (Weekly Average) in the Post-treatment Observation Period - Change From Last Day of Double-blind Treatment Period (Day 28) [ Time Frame: Participants assessed and recorded their pain level daily. Weekly averages were calculated for the Day 35, Day 42 and Day 49 assessments ]

    Participants assessed their pain levels by using the 0-10 Numeric Rating Scale: 0 = No pain 1-3 = Mild pain (nagging, annoying, interfering little with activities of daily living [ADLs]) 4-6 = Moderate pain (interferes significantly with ADLs) 7-10 = Severe pain (disabling; unable to perform ADLs A negative mean change denotes a pain decrease. A positive mean change denotes an increase in pain. Baseline was defined as the most recent value obtained on the last day of the double-blind dosing period (Day 28).

    Category title includes number of participants with available data (n) for participants treated with study product, followed by participants treated with placebo.


  • Numerical Pain Rating Scale (NPRS): Worst Pain (Weekly Average) in the Post-treatment Observation Period - Change From Last Day of Double-blind Treatment Period (Day 28) - AUC [ Time Frame: Participants assessed and recorded their pain level daily. Weekly averages were calculated for the Day 35, Day 42 and Day 49 assessments ]
    Participants assessed their pain levels by using the 0-10 Numeric Rating Scale: 0 = No pain 1-3 = Mild pain (nagging, annoying, interfering little with activities of daily living [ADLs]) 4-6 = Moderate pain (interferes significantly with ADLs) 7-10 = Severe pain (disabling; unable to perform ADLs A negative mean change denotes a pain decrease. A positive mean change denotes an increase in pain. Baseline was defined as the most recent value obtained on the last day of the double-blind dosing period (Day 28). Area under the curve (AUC) was computed using change from baseline (Day 28) in weekly average values at Day 35, Day 42 and Day 49.

  • Brief Pain Inventory (BPI): Average Pain Level in Last 24 Hours (Double-blind Treatment Period) - Change From Baseline [ Time Frame: At baseline, Day 7 and Day 28 during the double-blind treatment period ]

    Participants rated the severity of their pain by using the BPI short form. Pain was rated on a scale from 0 (no pain) to 10 (pain as bad as you can imagine). A negative mean change denotes a pain decrease. A positive mean change denotes an increase in pain.

    Baseline was defined as the most recent value obtained prior to the start of the dosing on Day 1 of the double-blind dosing period.

    Category title includes number of participants with available data (n) for participants treated with study product, followed by participants treated with placebo.


  • Brief Pain Inventory (BPI): Worst Pain Level in Last 24 Hours (Double-blind Treatment Period) - Change From Baseline [ Time Frame: At baseline, Day 7 and Day 28 during the double-blind treatment period ]

    Participants rated the severity of their pain by using the BPI short form. Pain was rated on a scale from 0 (no pain) to 10 (pain as bad as you can imagine). A negative mean change denotes a pain decrease. A positive mean change denotes an increase in pain.

    Baseline was defined as the most recent value obtained prior to the start of the dosing on Day 1 of the double-blind dosing period.

    Category title includes number of participants with available data (n) for participants treated with study product, followed by participants treated with placebo.


  • Brief Pain Inventory (BPI): Worst Pain Level in Last 24 Hours (Post-treatment Observation Period) - Change From Baseline [ Time Frame: At baseline and Day 49 during the post-treatment observation period ]

    Participants rated the severity of their pain by using the BPI short form. Pain was rated on a scale from 0 (no pain) to 10 (pain as bad as you can imagine). A negative mean change denotes a pain decrease. A positive mean change denotes an increase in pain.

    Baseline was defined as the most recent value obtained prior to the start of the dosing on Day 1 of the double-blind dosing period.


  • Brief Pain Inventory (BPI): Interference of Pain With Aspects of Life (General Activity) During Double-blind Treatment Period - Change From Baseline [ Time Frame: At baseline, Day 7 and Day 28 during the double-blind treatment period ]

    Participants rated the degree to which their pain interfered with various daily functions by using the BPI short form. Interference with general activity was rated on a scale from 0 (does not interfere) to 10 (completely interferes).

    Baseline was defined as the most recent value obtained prior to the start of the dosing on Day 1 of the double-blind dosing period.

    Category title includes number of participants with available data (n) for participants treated with study product, followed by participants treated with placebo.


  • Brief Pain Inventory (BPI): Interference of Pain With Aspects of Life (General Activity) During Post-treatment Observation Period - Change From Baseline [ Time Frame: At baseline and Day 49 during the post-treatment observation period ]

    Participants rated the degree to which their pain interfered with various daily functions by using the BPI short form. Interference with general activity was rated on a scale from 0 (does not interfere) to 10 (completely interferes).

    Baseline was defined as the most recent value obtained prior to the start of the dosing on Day 1 of the double-blind dosing period.


  • Analgesic Use [ Time Frame: Throughout the study period (approximately 9 weeks) ]
    Analgesic use assessed with pain levels by numerical pain rating scale (NPRS) and brief pain inventory (BPI).

  • Reduction in Sickle Cell-specific Complications [ Time Frame: Throughout the study period (approximately 9 weeks) ]

Enrollment: 35
Study Start Date: October 2013
Study Completion Date: March 2015
Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort A (Drug)
Subjects randomized 3:1 to receive 4 times daily dosing of 1,000 mg of Aes 103 or placebo for 28 days
Drug: Aes-103
The active ingredient in Aes-103 is 5-hydroxymethyl furfural (5-HMF). Aes-103 and matching placebo are administered in a liquid oral formulation.
Placebo Comparator: Cohort A (Placebo)
Subjects randomized 3:1 to receive 4 times daily dosing of 1,000 mg of Aes 103 or placebo
Other: Placebo
Experimental: Cohort B (Drug)
In this adaptive design, the dose frequency and the total amount given per day to Cohort B will be adjusted depending on the tolerability, clinical pharmacology and clinical endpoint results of Cohort A. Study terminated prior to completion of Cohort A due to unblinding between study product and placebo groups for participant, site and Sponsor. The study was stopped before initiation of Cohort B.
Drug: Aes-103
The active ingredient in Aes-103 is 5-hydroxymethyl furfural (5-HMF). Aes-103 and matching placebo are administered in a liquid oral formulation.
Placebo Comparator: Cohort B (Placebo)
The dosing regiment of placebo will match that of the Aes-103 treatment in Cohort B. Study terminated prior to completion of Cohort A due to unblinding between study product and placebo groups for participant, site and Sponsor. The study was stopped before initiation of Cohort B.
Other: Placebo

Detailed Description:
This study will evaluate evaluate in subjects with stable SCD the safety, pharmacokinetic profile, clinical pharmacology actions and clinical activities of two dosing regimens of Aes-103 (1000 mg four times daily in Cohort A and a higher or lower dose given once daily or up to four times daily in Cohort B) given for up to 28 days in adult subjects with stable SCD compared with subjects receiving placebo.
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, aged 18-60 years old, inclusive
  • Diagnosis of SCD (hemoglobin SS) without hospitalization for pain crises or any other reason in the 14 days before enrollment
  • Have normal organ function as defined by direct bilirubin <1.1 mg/dL (19 μmol/L), alanine transaminase (serum glutamic pyruvic transaminase) ≤120 IU/L, and Creatinine ≤1.3 mg/dL (115 μmol/L)
  • Have at least one of the following baseline values: hemoglobin level of <10 g/dL, numerical pain rating scale (NPRS) score of ≥ 4, or 6-minute walk distance (6MWD) of <500 m
  • If female, be nonpregnant and nonbreastfeeding and be surgically sterile or using an acceptable method of contraception throughout the study and for 3 months after the last dose of study medication
  • Have completed an outpatient screening visit consisting of medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs, hematology and chemistry tests, urinalysis, urine drug screen, urine or serum pregnancy test (females), hemoglobin electrophoresis, hepatitis B and C screening, and HIV serology
  • Be able to understand and have provided written informed consent including signature on an informed consent form approved by an institutional review board or independent ethics committee
  • Have provided written authorization for use and disclosure of protected health information
  • Agree to abide by the study schedule and to return for the required assessments

Exclusion Criteria:

  • Have been hospitalized in the 14 days before enrollment, for any reason
  • Have evidence of clinically significant cardiovascular, respiratory, renal, hepatic, pulmonary, gastrointestinal, hematological, neurological, psychiatric, or other disease that may interfere with the objectives of the study or the safety of the subject, or have been hospitalized in the past 6 months as a result of these conditions (for SCD-related morbidity, a minimum of 14 days from the last hospitalization is required)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01987908

Locations
United Kingdom
Quintiles Ltd. - Quintiles Drug Research Unit, 6 Newcomen Street
London, United Kingdom, SE1 1YR
Sponsors and Collaborators
Baxalta US Inc.
Investigators
Study Director: Brahm Goldstein, MD Baxalta US Inc.
  More Information

Responsible Party: Baxalta US Inc.
ClinicalTrials.gov Identifier: NCT01987908     History of Changes
Other Study ID Numbers: Aes-103-003
321401 ( Other Identifier: Baxalta )
Study First Received: October 29, 2013
Results First Received: June 21, 2016
Last Updated: February 3, 2017

Keywords provided by Baxalta US Inc.:
Pain
Biomarkers
6 minute walk test
5-HMF
Pharmacokinetics
Analgesic use
Sickle cell disease
Aes-103
SpO2
Anemia
Hemoglobin

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on May 24, 2017